Iqra Syed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iqra Syed has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Springford
AstraZeneca Canada, Mississauga, ON, Canada
1 shared publication - Aliyah Pabani
The Sidney Kimmel Comprehensive Cancer Center 1 , Johns Hopkins University School of Medicine, Baltimore, Maryland
1 shared publication Bertrand Routy
Centre de recherche CHUM (CRCHUM), Université de Montréal, Montréal, QC, Canada
1 shared publication- Charley Cooper1 shared publication
- Chelsea McKibbon
Cytel, Toronto, ON, Canada
1 shared publication - Cheryl Ho
BC Cancer, Vancouver, BC, Canada
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Multidisciplinary team perceptions towards the treatment of limited-stage small-cell lung cancer; a United States physician survey
Background Treatment paradigms for limited-stage small cell lung cancer (LS-SCLC) have remained unchanged for decades, focusing on multi-disciplinary team (MDT) coordination, with treatments including concurrent chemoradiotherapy (cCRT) for the majority of patients, with optional prophylactic cranial irradiation (PCI). With the introduction of immunotherapy (IO) for LS-SCLC, there is a need to assess the real-world application of current treatment guidance. Methods Cross-sectional survey of medical oncologists (MedO) and radiation oncologists (RadO) in the US, conducted August-October 2024. Oncologists reported on their use of cCRT and PCI, and their views on upcoming IO therapies. Results Of the 177 oncologists (MedO: n=87; RadO: n=90), 94.9% reported attending an MDT, with 53.4% reporting weekly MDT meetings. Oncologists stated that among their LS-SCLC patients receiving CRT,a median 90.0% (IQR: 55.0%, 95.0%) of them received cCRT, most commonly with cisplatin/etoposide (55.4%). Common barriers to cCRT use were patient comorbidities (48.6%) and treatment toxicity (46.9%). Facilitators included presence of a nurse navigator (59.8%). Half of patients typically received PCI, with concern about patient cognitive decline (54.9%) and patient refusal (53.7%) being the most common reasons for PCI deferral. The majority of physicians were familiar with upcoming IO therapies, and likely to prescribe them. Side effects (37.9%) and radiotherapy-related pneumonitis (32.8%) were the most commonly reported reasons for not prescribing IO. Conclusion Although cCRT is commonly used, barriers remain, highlighting need for less burdensome treatments. A high reported likelihood of prescribing emerging IO therapies suggests a shift towards improved patient and clinical outcomes in routine clinical practice.
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMultidisciplinary team perceptions towards the treatment of limited-stage small-cell lung cancer; a United States physician survey
Background Treatment paradigms for limited-stage small cell lung cancer (LS-SCLC) have remained unchanged for decades, focusing on multi-disciplinary team (MDT) coordination, with treatments including concurrent chemoradiotherapy (cCRT) for the majority of patients, with optional prophylactic cranial irradiation (PCI). With the introduction of immunotherapy (IO) for LS-SCLC, there is a need to assess the real-world application of current treatment guidance. Methods Cross-sectional survey of medical oncologists (MedO) and radiation oncologists (RadO) in the US, conducted August-October 2024. Oncologists reported on their use of cCRT and PCI, and their views on upcoming IO therapies. Results Of the 177 oncologists (MedO: n=87; RadO: n=90), 94.9% reported attending an MDT, with 53.4% reporting weekly MDT meetings. Oncologists stated that among their LS-SCLC patients receiving CRT,a median 90.0% (IQR: 55.0%, 95.0%) of them received cCRT, most commonly with cisplatin/etoposide (55.4%). Common barriers to cCRT use were patient comorbidities (48.6%) and treatment toxicity (46.9%). Facilitators included presence of a nurse navigator (59.8%). Half of patients typically received PCI, with concern about patient cognitive decline (54.9%) and patient refusal (53.7%) being the most common reasons for PCI deferral. The majority of physicians were familiar with upcoming IO therapies, and likely to prescribe them. Side effects (37.9%) and radiotherapy-related pneumonitis (32.8%) were the most commonly reported reasons for not prescribing IO. Conclusion Although cCRT is commonly used, barriers remain, highlighting need for less burdensome treatments. A high reported likelihood of prescribing emerging IO therapies suggests a shift towards improved patient and clinical outcomes in routine clinical practice.
- Open Access
- 14 May 2025
- Published by Elsevier in Lung Cancer
- Vol. 204, 108583
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
- 14 May 2025
- Published by Elsevier in Lung Cancer
- Vol. 204, 108583
Open AccessReal-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study